Found 6 articles for: "Clascoterone cream"
Clascoterone Cream 1% is Safe and Effective for Papulopustular Rosacea: A Phase 2 Clinical Trial
August 2026 | Volume 25 | Issue 8 | Original Article | 701 | Copyright © August 2026
Background: Papulopustular rosacea (PPR) is a chronic inflammatory facial dermatosis with a need for well-tolerated and effective topical therapies. Clascoterone cream 1% is an a...
Read MoreEfficacy and Safety of Clascoterone Cream 1% and Adapalene Gel 0.3% in Patients With Acne
June 2026 | Volume 25 | Issue 6 | Original Article | 545 | Copyright © June 2026
Background: Clascoterone cream 1% is a topical androgen receptor inhibitor approved for the treatment of acne vulgaris in patients ≥12 years of age. The American Academy of De...
Read MoreEfficacy and Safety of Clascoterone Cream 1% and Clindamycin 1.2%/Benzoyl Peroxide 5% Gel Treatment in Patients With Acne
June 2026 | Volume 25 | Issue 6 | Original Article | 537 | Copyright © June 2026
Background: Clascoterone cream 1% is a topical androgen receptor inhibitor approved to treat acne vulgaris in patients ≥12 years of age. The American Academy of Dermatology re...
Read MoreImprovement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1%
April 2025 | Volume 24 | Issue 4 | Original Article | 397 | Copyright © April 2025
Background: Topical medications commonly prescribed for the treatment of acne vulgaris may be limited by application-site dryness, which can result in skin barrier damage. This s...
Read MoreIntegrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris
January 2024 | Volume 23 | Issue 1 | Original Article | 1278 | Copyright © January 2024
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged 12 years or older based on results from two identical pivotal Phase 3 trials. In...
Read MoreEfficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
February 2023 | Volume 22 | Issue 2 | Original Article | 174 | Copyright © February 2023
Background: Two randomized phase 3 studies evaluated efficacy and safety of 1% clascoterone cream, a topical androgen receptor inhibitor, in patients aged ≥9 years with modera...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
